Steroid treatment: the long and the short of it

Article

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

Nhung Xuan Nguyen and colleagues from the University of Erlangen-Nürnberg, Germany, compared the effects of long- and short-term topical steroid use on endothelial cell counts in 305 subjects. All patients, after undergoing PK, received prednisolone acetate 1% eye drops five times a day. This was slowly tapered over a six-month period. Patients were randomly assigned to the short-term group, which ceased steroid treatment, or the long-term group, which continued with the treatment once daily for a further 12 months.

A significant postoperative decrease in endothelial cell density was observed in both groups. At six-week follow-up, cell densities averaged 1,941 cells/mm2 in the short-term group and 1,957 cells/mm2 in the long-term group. At two-year follow-up, cell density had decreased significantly to 1,535 cells/mm2 and 1,472 cells/mm2, respectively (p<0.001).

Using linear regression, the researchers calculated that subjects in the short-term group lost an average of 216 cells/mm2 per year, while those in the long-term group lost an average of 206 cells/mm2 (p=0.5).

Analysis of the results revealed that there is no significant difference in cell density between patients on long- and short-term steroid treatment following penetrating keratoplasty.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.